TL;DR
- •Ketamine is an NMDA-receptor antagonist legally prescribed off-label for PTSD and depression. MDMA-assisted therapy uses 3,4-methylenedioxymethamphetamine as a Schedule I substance to facilitate trauma-focused psychotherapy.
- •Mitchell 2021 (Nat Med, MAPP1) and Mitchell 2023 (Nat Med, MAPP2) showed MDMA-assisted therapy produced statistically and clinically significant PTSD symptom reduction in severe and moderate-severe PTSD respectively.
- •In August 2024, FDA rejected the MAPS/Lykos MDMA-PTSD application — citing concerns about trial design, blinding, and adverse event reporting. MAPS continues working toward resubmission; broad legal access remains years away.
- •Ketamine has decades of safety data, legal prescription status, and at-home administration options. MDMA remains Schedule I outside of expanded-access compassionate-use protocols.
- •Both treatments work alongside psychotherapy — MDMA-assisted therapy uses three 8-hour MDMA-assisted sessions interleaved with multiple non-drug therapy sessions; ketamine for PTSD typically uses 4-8 induction sessions with optional integration therapy.
- •For trauma patients who want a psychedelic-mechanism treatment available today, ketamine is the only legal at-home option in the US.
Side by side
Ketamine
Racemic ketamine (NMDA antagonist)
NMDA-receptor antagonist (off-label for psychiatric use)
What it treats
Off-label: PTSD, treatment-resistant depression, anxiety, FDA-approved: anesthesia, surgical sedation
Mechanism
NMDA-receptor antagonism producing acute glutamate surge, BDNF-mediated neuroplasticity, and reduced fear-memory consolidation. The brief dissociative state may decrease emotional reactivity to traumatic content, allowing easier therapeutic processing.
Strengths
- •Legal and prescribable today — sublingual at-home option available
- •Rapid onset (hours to first session response)
- •Decades of safety data in anesthesia
- •Maintenance dosing flexibility based on response
Limitations
- •Less PTSD-specific evidence than MDMA trials
- •Off-label use — not FDA-approved for PTSD
- •Most clinicians don't provide integrated therapy alongside ketamine in the same session
- •Maintenance dosing required for many patients
MDMA-Assisted Therapy
MDMA-assisted psychotherapy
Empathogen + structured psychotherapy (Schedule I)
What it treats
Investigational: PTSD (FDA rejected approval August 2024, MAPS resubmission pending)
Mechanism
MDMA releases serotonin, norepinephrine, and dopamine while increasing oxytocin and reducing amygdala fear response. The empathogenic, emotionally open state allows patients to engage with traumatic memories with reduced fear and shame, working with two therapists across three 8-hour sessions.
Strengths
- •Strong Phase 3 PTSD evidence — Mitchell 2021/2023 (Nat Med) both met primary endpoints
- •Three-session protocol may produce durable response without ongoing maintenance
- •Integrated psychotherapy is built into the protocol (not optional)
- •Lower abuse potential than recreational MDMA use in therapeutic-protocol context
Limitations
- •FDA rejected approval August 2024 — not currently legally accessible outside clinical trials and compassionate use
- •High cost ($10,000-$15,000+ per course of three sessions if/when legally approved)
- •Requires two-therapist team for each 8-hour session — major access constraint
- •Cardiovascular risk (raises BP/HR) — contraindicated in cardiac disease
- •MAPS resubmission timeline uncertain — broad access years away
Which one for your situation?
If:
PTSD patient who wants treatment available today
Verdict:
Ketamine — legally accessible now; MDMA-assisted therapy is not currently approved
If:
Strong preference for integrated psychedelic + psychotherapy in a single session
Verdict:
MDMA-assisted therapy (when available) — protocol built around in-session therapy
If:
Cardiovascular contraindication (hypertension, cardiac disease)
Verdict:
Ketamine (with screening) — MDMA's cardiovascular load is a hard contraindication for many patients
If:
Treatment-resistant depression alongside PTSD
Verdict:
Ketamine — broader evidence in depression specifically; can also help PTSD symptoms
If:
Currently enrolled in an MDMA-PTSD clinical trial
Verdict:
Continue trial — supervised research-grade MDMA access is rare and valuable
Where ketamine fits
Tovani provides sublingual ketamine via telehealth in Florida and New Jersey — the legally-accessible psychedelic-mechanism option for PTSD and treatment-resistant depression. For patients drawn to MDMA-assisted therapy but unable to access it (no FDA approval, clinical trial unavailable), ketamine offers a related but mechanistically distinct option.
Ketamine: response often within hours of the first session. MDMA-assisted therapy: response measured across the three-session protocol over 12+ weeks. Ketamine is legally accessible today; MDMA-assisted therapy is not, outside trials.
5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Will MDMA-assisted therapy be FDA-approved soon?
Unclear. FDA rejected MAPS/Lykos' application in August 2024, citing concerns about trial design, blinding integrity, and adverse event reporting. MAPS continues to work toward resubmission. Realistic timelines for approval are 2027 or later, contingent on additional trials addressing FDA's concerns.
Is MDMA available outside clinical trials?
In the US, no — MDMA remains Schedule I. Some patients access expanded-access compassionate-use protocols through MAPS or research sites. Australia legalized psychiatrist-prescribed MDMA-assisted therapy in July 2023 with limited availability and high costs (~$15,000-25,000 per course). Recreational MDMA is unregulated, unsafe, and not therapeutic.
Can ketamine help PTSD?
Yes — ketamine has evidence in PTSD treatment, though less specific than MDMA-assisted therapy trials. The NMDA-glutamate mechanism affects fear-memory consolidation and reactivity. Many patients with comorbid PTSD and depression respond to ketamine on both dimensions. For PTSD alone (without depression), evidence is emerging; for comorbid presentations, ketamine has been more widely studied.
How is the experience different from MDMA?
Ketamine produces a brief (60-120 minute therapeutic-dose) dissociative experience with emotional detachment. MDMA produces a longer (4-6 hour) emotionally open, empathogenic state with intact ego and active engagement. Therapeutic models differ — ketamine therapy is often less structured around in-session content; MDMA-assisted therapy is built around therapist-guided trauma processing during the session.
Which has better evidence for PTSD specifically?
MDMA-assisted therapy has stronger PTSD-specific Phase 3 trial data (Mitchell 2021/2023). Ketamine has more rapidly-actionable evidence in depression with PTSD comorbidity. For pure PTSD without depression, MDMA-assisted therapy's evidence is currently stronger — but the regulatory pathway is uncertain and the treatment is not currently accessible to most US patients.
References
- Mitchell JM et al. 2021, Nature Medicine (MAPP1). Phase 3 RCT of MDMA-assisted therapy for severe PTSD — 67% of MDMA participants no longer met PTSD criteria at 18-week follow-up vs 32% in placebo + therapy. PMID 33972795
- Mitchell JM et al. 2023, Nature Medicine (MAPP2). Phase 3 RCT of MDMA-assisted therapy for moderate-to-severe PTSD — replicated MAPP1 efficacy in a broader patient population. PMID 37709999
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — 64% response vs 28% placebo, establishing the rapid-onset antidepressant mechanism relevant to comorbid PTSD-depression. PMID 23982301
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine's rapid effects in mood and stress-related disorders. PMID 28249076